Oxidative stress and small, dense low-density lipoproteins: Current and future perspectives

Expert Review of Endocrinology and Metabolism

Volumn 7, Issue 4, 2012, Pages 415-417

  Rizvi, Ali A ^a   Montalto, Giuseppe ^b   Patti, Angelo Maria ^b   Rizzo, Manfredi ^a,b,c  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c Euro Mediterranean Institute of Science and Technology   (Italy)

Author keywords

cardiovascular risk; dense LDL; dyslipidemia; low density lipoprotein; oxidative stress; small

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FRACTIONATION; NOTE; OXIDATIVE STRESS; PARTICLE SIZE; PRIORITY JOURNAL;

EID: 84864632803     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.12.30     Document Type: Note

References (20)

1. Kotani K, Tsuzaki K, Taniguchi N, Sakane N. LDL particle size and reactive oxygen metabolites in dyslipidemic patients. Int. J. Prev. Med. 3(3), 160-166 (2012).
2. Rizzo M, Berneis K. Who needs to care about small, dense low-density lipoproteins? Int. J. Clin. Pract. 61(11), 1949-1956 (2007).
3. Rizzo M, Berneis K, Corrado E, Novo S. The significance of low-density-lipoproteins size in vascular diseases. Int. Angiol. 25(1), 4-9 (2006).
4. Mikhailidis DP, Elisaf M, Rizzo M et al. European panel on low density lipoprotein (LDL) subclasses: A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: Executive summary. Curr. Vasc. Pharmacol. 9(5), 531-532 (2011).
5. Mikhailidis DP, Elisaf M, Rizzo M et al. 'European panel on low density lipoprotein (LDL) subclasses': A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol. 9(5), 533-571 (2011).
6. Hirose H, Kawabe H, Komiya N, Saito I. Relations between serum reactive oxygen metabolites (ROMs) and various inflammatory and metabolic parameters in a Japanese population. J. Atheroscler. Thromb. 16(2), 77-82 (2009).
7. Rizzo M, Kotur-Stevuljevic J, Berneis K et al. Atherogenic dyslipidemia and oxidative stress: A new look. Transl. Res. 153(5), 217-223 (2009).
8. Rizvi AA. Hypertension, obesity, and inflammation: The complex designs of a deadly trio. Metab. Syndr. Relat. Disord. 8(4), 287-294 (2010).
9. Rizvi AA. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: Emerging concepts. Am. J. Med. Sci. 338(4), 310-318 (2009).
10. Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 49(4), 766-774 (2006).
11. Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am. J. Cardiol. 96(9), 1266-1272 (2005).
12. Mori Y, Itoh Y, Obata T, Tajima N. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with Type 2 diabetes. Endocrine 29(1), 143-148 (2006).
13. Berneis K, Rizzo M, Stettler C et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. Expert Opin. Pharmacother. 9(3), 343-349 (2008).
14. Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with Type-2 diabetes. Exp. Clin. Endocrinol. Diabetes 115(8), 477-482 (2007).
15. Rizzo M, Berneis K, Koulouris S et al. Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with Type 2 diabetes? Int. J. Clin. Pract. 64(12), 1632-1642 (2010).
16. Corrado E, Rizzo M, Muratori I, Coppola G, Novo S. Association of elevated fibrinogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or Type II diabetes. Arch. Med. Res. 37(8), 1004-1009 (2006).
17. Rizzo M, Mikhailidis DP. There is more to predicting vascular disease than just established risk factors. Curr. Pharm. Des. 17(33), 3608-3610 (2011).
18. Barbagallo CM, Polizzi F, Severino M et al. ApoE polymorphism in a small Mediterranean island: Relationships with plasma lipids, lipoproteins and LDL particle size. Eur. J. Epidemiol. 17(8), 707-713 (2001).
19. Rizzo M, Berneis K, Hersberger M et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum. Reprod. 24(9), 2286-2292 (2009).
20. Rizzo M, Pernice V, Frasheri A et al. Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin. Endocrinol. 70(6), 870-875 (2009).